
Adilia Hormigo, MD, PhD
- PROFESSOR | Neurosurgery
- PROFESSOR | Medicine
- PROFESSOR | Neurology
Adilia Hormigo, MD, PhD is Professor in the Department of Neurology, Medicine (Division of Hematology-Oncology), and Neurosurgery. She is a neuro-oncologist specializing in the care of patients with primary brain tumors, CNS metastases, and the neurological complications of cancer and its treatment. She employs a multidisciplinary team approach to ensure that patients receive compassionate, comprehensive care.
Dr. Hormigo obtained her MD with honors from the University of Lisbon Medical School in Portugal, and her PhD from New York University. She completed residencies in Neurology at the University Hospital of Lisbon Medical School, Portuguese Oncological Institute and New York Presbyterian-Weill Medical College of Cornell University and Memorial Sloan-Kettering Cancer Center. She completed both research and clinical neuro-oncology fellowships under Jerome B. Posner. She served as faculty at Memorial Sloan-Kettering Cancer Center and Cornell University. She trained a number of fellows, many of whom are faculty in leading programs of neuro-oncology in the country and abroad.
Her clinical and translational research focuses on new strategies including personalized treatment for patients with brain tumors with emphasis on immunotherapy, developing new biomarkers and studying the microenvironment of brain tumors. Her goal is to achieve the highest level of patient care and clinical excellence.
Videos
Education
Research Fellow, Memorial Sloan-Kettering Cancer Center
PhD, New York University
Fellow, Memorial Sloan-Kettering Cancer Center
-
2013
Fellow -
2012
Advanced Techniques in Molecular Neuroscience -
2005
Excellence in Teaching Award for the Neurology Clerkship -
2003
Resident Award -
1990
Second UCB Neurology Award -
1989
Biofarma
Developing Personalized Medicine to Treat Patients with Brain Tumors
Dr. Hormigo's research focuses on developing personalized medicine to treat patients with brain tumors. She uses a multidisciplinary approach that includes neuropathology, bioinformatics, biochemistry and the Cancer Vaccine and Cell Therapy laboratory at the Tisch Cancer Institute to develop a new immunotherapy-based treatment. Mutations in glioblastoma lead to the formation of neoantigens. These neoantigens are not present in normal cells. Her treatment targets those neoantigens of tumors and it is given to the patient in a form of vaccine to activate the immune system and eliminate the cancer cells. Her team is also developing new methods to increase drug penetration to the brain and to determine other approaches that will enhance the effect of immunotherapy.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Hormigo is not currently required to report Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.